1. **Treatment & Condition**
   Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis.

2. **Associated appraisal body & Summary of ruling**
   NICE Technology Appraisal guidance TA590 (July 2019)
   Fluocinolone acetonide intravitreal implant (Iluvien®) is recommended, within its marketing authorisation, as an option for preventing relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. It is recommended only if the company provides it according to the commercial arrangement.

3. **Number of people in Northern Ireland expected to take up service/therapy**
   Implementation of this guidance offers an additional treatment option for preventing relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.
   The NICE resource impact statement indicates that the guidance is not expected to have an impact on resources. This is because the technology is an option alongside current standard treatment options.

4. **Patient Access Scheme Availability**
   (Yes/No)
   The company (Alimera Sciences) has a commercial arrangement. This makes fluocinolone acetonide intravitreal implant available to the NHS with a discount. The size of the discount is commercial in confidence.

5. **Infrastructure Requirements**
   The implementation of NICE TA590 is unlikely to result in significant change in infrastructure requirements. The HSC Board will work with Trusts to identify how the requirements compare to current infrastructure needs.

6. **Expected implementation period**
   There is no impediment to immediate implementation for new patients on a cost per case basis. This will allow patient numbers to be monitored.

7. **Commissioning arrangements**
   This treatment will be formally commissioned from Trusts by the HSCB/PHA via the Specialist Services Commissioning Team. This regime will be consolidated into the commissioning arrangements in place for macular services.
8. **Monitoring arrangements**

The HSC Board will incorporate information on this regime into the existing monthly monitoring arrangements with Trusts for monitoring patients with the range of macular conditions.

A monitoring report will be submitted to the Specialist Services Commissioning Team on a regular basis for formal review and comment by the team. Ongoing meetings between the HSC Board, PHA and Trusts will continue.

9. **DoH (NI) Legislative/Policy Caveats**

This advice does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.

The Rural Needs Act NI 2016 has been considered and this guidance, which is purely of a technical nature, is not regarded as falling within the scope of the act.